Scarica l'app Stockscreener
7.05
1.67%
-0.12
Dopo l'orario di chiusura:
7.05
Precedente Chiudi:
$7.17
Aprire:
$7.17
Volume 24 ore:
1.47M
Relative Volume:
0.62
Capitalizzazione di mercato:
$1.17B
Reddito:
$246.03M
Utile/perdita netta:
$-32.00M
Rapporto P/E:
-33.18
EPS:
-0.2125
Flusso di cassa netto:
$-16.78M
1 W Prestazione:
+0.86%
1M Prestazione:
-1.81%
6M Prestazione:
+62.07%
1 anno Prestazione:
+114.94%
Intervallo 1D:
$7.02
$7.25
Intervallo di 1 settimana:
$6.854
$7.30
Portata 52W:
$3.14
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Nome
Xeris Biopharma Holdings Inc
Settore
Industria
Telefono
844-445-5704
Indirizzo
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Confronta XERS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
7.05 | 1.19B | 246.03M | -32.00M | -16.78M | -0.2125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-08-12 | Ripresa | H.C. Wainwright | Buy |
| 2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2023-08-28 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Craig Hallum | Buy |
| 2021-11-17 | Iniziato | SVB Leerink | Outperform |
| 2021-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-02-18 | Iniziato | Piper Sandler | Overweight |
| 2018-07-16 | Iniziato | Jefferies | Buy |
| 2018-07-16 | Iniziato | Leerink Partners | Outperform |
| 2018-07-16 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Xeris Biopharma Holdings Inc Borsa (XERS) Ultime notizie
Insider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells 15,000 Shares of Stock - MarketBeat
Insider Sell: Barbara-jean Bormann-kennedy Sells 15,000 Shares o - GuruFocus
Walleye Capital LLC Sells 448,444 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Jump Financial LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
561,700 Shares in Xeris Biopharma Holdings, Inc. $XERS Bought by Norges Bank - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Coverage Initiated at Barclays - MarketBeat
Barclays Initiates Coverage on Xeris Biopharma Holdings (XERS) w - GuruFocus
Xeris Biopharma (XERS): Valuation Check After USPTO Notice of Allowance for Weekly Levothyroxine XP-8121 Patent - Sahm
Xeris Biopharma’s (XERS) Positioning Strengthens After Reaching Product Pipeline Milestone - Insider Monkey
7 Hidden Multibagger Stocks to Invest In - Insider Monkey
Xeris Biopharma Holdings (XERS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? - Yahoo Finance
Is Xeris Biopharma (XERS) Using XP-8121 Patents to Quietly Redefine Its Long-Term Growth Story? - Sahm
How Xeris Biopharma Holdings Inc. stock performs in weak economy2025 Price Momentum & Verified Trade Idea Suggestions - Newser
Why Xeris Biopharma Holdings Inc. (2B30) stock is favored by hedge funds2025 Momentum Check & Fast Gain Stock Tips - Newser
What Wall Street predicts for Xeris Biopharma Holdings Inc. stock price2025 Major Catalysts & Verified High Yield Trade Plans - Newser
How higher bond yields impact Xeris Biopharma Holdings Inc. (2B30) stockJuly 2025 Opening Moves & Community Verified Watchlist Alerts - Newser
Xeris Biopharma (NASDAQ:XERS) Insider Sells $116,835.67 in Stock - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Shares Down 4.9%Here's Why - MarketBeat
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings - Yahoo Finance
What is Xeris Biopharma Holdings Inc (XERS) Stock Return on Shareholders’ Capital? - Setenews
Risks Still Elevated At These Prices As Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Dive 35% - simplywall.st
Legal & General Group Plc Purchases 392,589 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Is Xeris Biopharma Holdings Inc. stock a safe buy before earningsEarnings Growth Summary & Safe Capital Growth Plans - Newser
Why Xeris Biopharma Holdings Inc. (2B30) stock appeals to dividend investorsMarket Risk Analysis & Growth Focused Entry Reports - Newser
Hecht Beth, Xeris Biopharma chief legal officer, sells $116k in XERS - Investing.com India
Hecht Beth, Xeris Biopharma chief legal officer, sells $116k in XERS By Investing.com - Investing.com South Africa
Xeris Biopharma Holdings Director Beth Hecht Sells Shares - TradingView
Officer Hecht Sells 16,667 ($116.8K) Of Xeris Biopharma Holdings Inc [XERS] - TradingView
Oversold Conditions For Xeris Biopharma Holdings (XERS) - Nasdaq
Why Xeris Biopharma Holdings Inc. (2B30) stock is listed among top recommendations2025 Institutional Moves & Daily Stock Momentum Reports - Newser
A Look at Xeris Biopharma (XERS) Valuation After Patent Progress on Novel Hypothyroidism Therapy - Sahm
Xeris Pharmaceuticals Secures Patent Allowance for XP-8121 - MSN
Xeris Biopharma receives patent allowance for hypothyroidism drug By Investing.com - Investing.com Australia
Is Xeris Biopharma Holdings Inc 2B30 a good long term investmentPrice Action Analysis & Small Investment Growth Tips - earlytimes.in
Xeris Biopharma Receives Notice of Allowance for XP-8121 Patent - marketscreener.com
Xeris BioPharma Holdings Incunit receives USPTO notice of allowance for XP-8121 patent - marketscreener.com
Xeris Biopharma (XERS) Advances with New Patent Approval - GuruFocus
Xeris Biopharma receives patent allowance for hypothyroidism drug - Investing.com
Xeris Biopharma Holdings, Inc. Receives Notice of Allowance for XP-8121 Patent - TradingView
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application - marketscreener.com
Xeris Biopharma (Nasdaq: XERS) receives USPTO Notice of Allowance for XP-8121 - Stock Titan
Prudential Financial Inc. Buys 457,784 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Intech Investment Management LLC Has $441,000 Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Geode Capital Management LLC Boosts Stock Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Adversity is less terrifying than hope: Xeris Biopharma Holdings Inc (XERS) - Setenews
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xeris Biopharma Holdings, Inc. $XERS Shares Acquired by CenterBook Partners LP - MarketBeat
What drives Xeris Biopharma Holdings Inc 2B30 stock priceDividend Stability Analysis & Stay Safe With Built-In Risk Monitoring - earlytimes.in
Xeris Biopharma Faces Weak Start with 15% Gap Down Amid Market Concerns - Markets Mojo
Will Xeris Biopharma Holdings Inc. (2B30) stock hit Wall Street targetsPortfolio Value Summary & Low Drawdown Investment Ideas - newser.com
Xeris Biopharma Holdings Inc Azioni (XERS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):